TABLE 1.
Clinical Features of the HCC Cohort
| Clinical Features | Category/Statistical Measurements | Training | Validation |
|---|---|---|---|
| Number of samples | Count | 38 | 26 |
| Latest recurrence status | Nonrecurrent | 23 | 18 |
| Recurrent | 15 | 8 | |
| Milan score | In | 16 (42.1%) | 20 (76.9%) |
| Out | 22 (57.9%) | 6 (23.1%) | |
| Tx age | Mean ± SD | 56.2 ± 8.9 | 61.9 ± 5.7 |
| Tx type | Orthotopic | 37 | 16 |
| Living related | 1 | 3 | |
| Living nonrelated | 0 | 7 | |
| Underlying disease | HBV | 5 (13.2%) | 0 (0.0%) |
| HCV | 17 (44.7%) | 9 (34.6%) | |
| Nodular regenerative hyperplasia | 1 (2.6%) | 0 (0.0%) | |
| Hemochromatosis | 2 (5.3%) | 0 (0.0%) | |
| NASH | 5 (13.2%) | 8 (30.8%) | |
| EtOH | 8 (21.1%) | 10 (38.5%) | |
| A1AT | 1 (2.6%) | 0 (0.0%) | |
| PBC | 1 (2.6%) | 1 (3.8%) | |
| NRH | 0 (0.0%) | 4 (15.4%) | |
| Orig. number of tumors | 1 | 10 | 9 |
| 2 | 8 | 6 | |
| 3 | 4 | 3 | |
| 4+ | 16 | 8 | |
| Orig. tumor sizes (cm) | [min, max] | [0.2, 21.0] | [0.3, 6.0] |
| Alive status at last follow‐up | Alive | 13 | 17 |
| Dead | 24 | 9 | |
| Unknown | 1 | 0 | |
| Pretransplant Rx | Y | 18 | 17 |
| N | 10 | 6 | |
| Unknown | 10 | 3 | |
| PreTx Rx type | RFA | 6 (15.8%) | 9 (34.6%) |
| Resection | 2 (5.3%) | 4 (15.4%) | |
| TACE | 13 (34.2%) | 14 (53.8%) | |
| Sorafenib | 0 (0.0%) | 5 (19.2%) | |
| None | 10 (26.3%) | 6 (23.1%) | |
| Immunosuppression | Tacrolimus | 18 (47.4%) | 25 (96.2%) |
| Mycophenolate | 11 (28.9%) | 25 (96.2%) | |
| Cyclosporine | 5 (13.2%) | 3 (11.5%) | |
| Everolimus | 3 (7.9%) | 14 (53.8%) | |
| Azathioprine | 0 | 4 (15.4%) | |
| mTOR inhibitor | Y | 3 | 13 |
| N | 28 | 12 | |
| Unknown | 7 | 1 | |
| Highest AFP level | [min, median, max] | [4, 40, 34,818] | [2.1, 34.05, 22,256] |
| HCC differentiation | Poor | 6 | 4 |
| Moderate | 21 | 17 | |
| Well | 11 | 5 | |
| Microvascular invasion | Yes | 23 | 14 |
| No | 13 | 12 | |
| Unknown | 2 | 0 | |
| Macrovascular invasion | Yes | 5 | 2 |
| No | 32 | 24 | |
| Unknown | 1 | 0 |
Abbreviations: A1AT, alpha‐1 antitrypsin deficiency; AFP, alpha‐fetoprotein; EtOH, ethanol; HBV, hepatitis B virus; HCV, hepatitis C virus; mTOR, mammalian target of rapamycin; N, no; NASH, nonalcoholic steatohepatitis; NRH, nodular regenerative hyperplasia; PBC, primary biliary cholangitis; RFA, radiofrequency ablation; Rx, prescription; TACE, transarterial chemoembolization; Tx, transplant; and Y , yes.